← Leaderboards
Karen S Slobod
St. Jude Children'S Research Hospital
$1,967,097
Attributed
$1,967,097
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $234K · FY2005–19$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,967,097 · 4
By mechanism
P01$1,296,597 · 2
R21$450,000 · 1
R34$220,500 · 1
Top collaborators
No co-investigators on record.
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Toru Takimoto$5,846,505
- Allen Portner$2,845,159
- Julia L Hurwitz$4,606,182
- Charles John Russell$2,338,253
- Christopher Coleclough$682,356
Others in their field
Top investigators on “Vector Vaccine”
- Lawrence Corey · Fred Hutchinson Cancer Center$446,547,761
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$239,426,049
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$142,420,923
- Peter B. Gilbert · Fred Hutchinson Cancer Center$124,587,333
- Louis J. Picker · Oregon Health And Science University$70,366,260
- David Heimbrook · Leidos Biomedical Research, Inc.$68,561,099
Research focus
Vector VaccineVaccine DevelopmentRecombinant VirusClinical ResearchAids VaccinesHiv Envelope ProteinHuman SubjectHumoral ImmunityAntigen Antibody ReactionRespiratory Syncytial VirusVaccine EvaluationAdultHuman Immunodeficiency Virus 1Parainfluenza Virus Type 1ChildParamyxovirus VaccineRecombinant ProteinsDrug Screening /EvaluationCellular ImmunityAidsImmune ResponseDoseImmunomodulatorsEvaluation
Grant awards (11)
A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Novel Live Attenuated Respiratory Syncytial Virus Vaccine with Thermal Stable Fusion protein in Seropositive Adults and Children$220,500
R34 · FY2019 · AI · contact PI
Clinical and Primate Paramyxovirus Vaccine Evaluation$233,951
P01 · FY2008 · AI · contact PI
Clinical and Primate Paramyxovirus Vaccine Evaluation$202,244
P01 · FY2007 · AI · contact PI
Clinical and Primate Paramyxovirus Vaccine Evaluation$219,392
P01 · FY2006 · AI · contact PI
Clinical and Primate Paramyxovirus Vaccine Evaluation$216,674
P01 · FY2005 · AI
Recombinant Sendai Virus as a Novel HIV Vaccine Vector$225,000
R21 · FY2004 · AI
Clinical and Primate Paramyxovirus Vaccine Evaluation$216,476
P01 · FY2004 · AI
Recombinant Sendai Virus as a Novel HIV Vaccine Vector$225,000
R21 · FY2003 · AI
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE$0
P01 · FY2002 · AI
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE$0
P01 · FY2001 · AI
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE$207,860
P01 · FY2000 · AI